Effect of aspirin on all-cause mortality in the healthy elderly

QR Code

Effect of aspirin on all-cause mortality in the healthy elderly

Background: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically high...

Full description

Bibliographic Details
Main Authors:	McNeil, J., Nelson, M., Woods, R., Lockery, J., Wolfe, R., Reid, Christopher, Kirpach, B., Shah, R., Ives, D., Storey, E., Ryan, J., Tonkin, A., Newman, A., Williamson, J., Margolis, K., Ernst, M., Abhayaratna, W., Stocks, N., Fitzgerald, S., Orchard, S., Trevaks, R., Beilin, L., Donnan, G., Gibbs, P., Johnston, C., Radziszewska, B., Grimm, R., Murray, A.
Format:	Journal Article
Published:	Massachusetts Medical Society 2018
Online Access:	http://hdl.handle.net/20.500.11937/74680

Similar Items

Effect of aspirin on disability-free survival in the healthy elderly
by: McNeil, J., et al.
Published: (2018)

Baseline Characteristics of Participants in the ASPREE (Aspirin in Reducing Events in the Elderly) Study
by: McNeil, J., et al.
Published: (2019)

Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study
by: McNeil, J., et al.
Published: (2017)

Effect of aspirin on cardiovascular events and bleeding in the healthy elderly
by: McNeil, J., et al.
Published: (2018)

The aspirin in reducing events in the elderly trial: Statistical analysis plan
by: Wolfe, R., et al.
Published: (2018)

ASPREE-D: Aspirin for the prevention of depression in the elderly
by: Berk, M., et al.
Published: (2016)

Quality of Life for 19,114 participants in the ASPREE (ASPirin in Reducing Events in the Elderly) study and their association with sociodemographic and modifiable lifestyle risk factors
by: Stocks, N., et al.
Published: (2018)

Impact of the 2017 AmericanHeart Association and American College of Cardiology hypertension guideline in aged individuals
by: Chowdhury, Enayet, et al.
Published: (2020)

Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.
by: Ryan, Joanne, et al.
Published: (2020)

The Study of Neurocognitive Outcomes, Radiological and Retinal Effects of Aspirin in Sleep Apnoea- rationale and methodology of the SNORE-ASA study
by: Ward, S., et al.
Published: (2018)

Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study
by: Robman, L., et al.
Published: (2017)

Normative performance of healthy older individuals on the Modified Mini-Mental State (3MS) examination according to ethno-racial group, gender, age, and education level
by: Ryan, J., et al.
Published: (2018)

Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial
by: Grimm, R., et al.
Published: (2013)

Factors associated with treatment and control of hypertension in a healthy elderly population free of cardiovascular disease: A Cross-sectional Study
by: Chowdhury, Enayet, et al.
Published: (2020)

Aspirin for the prevention of cognitive decline in the elderly: Rationale and design of a neuro-vascular imaging study (ENVIS-ion)
by: Reid, Christopher, et al.
Published: (2012)

Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial
by: Berk, M., et al.
Published: (2020)

Genetic variation in PEAR1, cardiovascular outcomes and effects of aspirin in a healthy elderly population
by: Lewis, J.P., et al.
Published: (2020)

Slowing the progression of age-related hearing loss: Rationale and study design of the ASPIRIN in HEARING, retinal vessels imaging and neurocognition in older generations (ASPREE-HEARING) trial
by: Lowthian, J., et al.
Published: (2016)

Effect of aspirin on cancer incidence and mortality in older adults.
by: McNeil, John J, et al.
Published: (2020)

Prevalence of chronic kidney disease in the elderly using the ASPirin in Reducing Events in the Elderly (ASPREE) study cohort
by: Polkinghorne, K., et al.
Published: (2019)

Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults
by: Mohebbi, M., et al.
Published: (2017)

Overcoming challenges to data quality in the ASPREE clinical trial
by: Lockery, J.E., et al.
Published: (2019)

Twisted Aspirin Crystals
by: Cui, X., et al.
Published: (2013)

Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective
by: Zomer, E., et al.
Published: (2018)

Dipyridamole plus aspirin versus aspirin alone in the secondary prevention after TIA or stroke: a meta-analysis by risk
by: Halkes, P.H.A., et al.
Published: (2008)

Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults
by: Zhou, Z., et al.
Published: (2020)

Associations of body size with all-cause and cause-specific mortality in healthy older adults
by: Carr, P.R., et al.
Published: (2023)

A multistate model of health transitions in older people: a secondary analysis of ASPREE clinical trial data
by: Neumann, J.T., et al.
Published: (2022)

Prediction of disability-free survival in healthy older people
by: Neumann, J.T., et al.
Published: (2022)

Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older Adults
by: Agustini, B., et al.
Published: (2020)

Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial
by: Islam, R.M., et al.
Published: (2022)

Optimising medication data collection in a large-scale clinical trial
by: Lockery, J.E., et al.
Published: (2019)

Simple Synthetic Receptors for Aspirin
by: Nguyen, Thanh Vinh, et al.
Published: (2014)

Cardiovascular risk prediction in healthy older people
by: Neumann, J.T., et al.
Published: (2022)

Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial
by: Bath, Philip M.W., et al.
Published: (2018)

Randomized factorial trial of esomeprazole and aspirin in Barrett’s oesophagus: the Aspirin and Esomeprazole Chemoprevention in Barrett’s metaplasia Trial (AspECT)
by: Jankowski, Janusz A.Z., et al.
Published: (2018)

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
by: Sacco, Ralph L., et al.
Published: (2008)

Social isolation, social support and loneliness as predictors of cardiovascular disease incidence and mortality
by: Freak-Poli, R., et al.
Published: (2021)

A randomised controlled trial of triple antiplatelet therapy (Aspirin, Clopidogrel and Dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility
by: Sprigg, Nikola, et al.
Published: (2008)

Protocol for a pilot randomised controlled clinical trial to compare the effectiveness of a graduated three layer straight tubular bandaging system when compared to a standard short stretch compression bandaging system in the management of people with venous ulceration: 3VSS2008
by: Weller, C., et al.
Published: (2010)